Bill Gates calls for drugs and potential vaccine to be given first to those who need them most Walt Disney World in Florida reopens, even as virus cases in the US state soar Iran admits it can’t afford to shut down its economy for a second time All updates in Universal Coordinated Time (UTC/GMT) 00:16 CanSino Biologics, a Chinese vaccine maker, is currently in talks with four countries — Russia, Brazil, Chile and Saudi Arabia — to launch a phase 3 trial of its experimental coronavirus vaccine. Qiu Dongxu, executive director and co-founder of the company, said that the trial would start “pretty soon” and CanSino would recruit 40,000 people for the trial. The company is currently constructing a new factory in China. CanSino expects to annually produce 100-200 million doses of the vaccine by early 2021, if it is approved. CanSino’s vaccine candidate, Ad5-nCov, was approved for testing on humans in March — becoming the first vaccine in China to achieve the feat. China has also approved two vaccine candidates by Sinovac Biotech and Sinopharm for phase 3 trials. 00:05 US President Donald Trump made his first public appearance with a face mask on Saturday at the Walter Reed National Military Medical Center in the state of Maryland. The president… Read full this story
- Diane Kruger and Norman Reedus stick tongues out in sweet mirror selfie as they wear face masks together
- New protests as Hong Kong government mulls face mask ban
- Protests over expected ban on face masks in Hong Kong
- Hong Kong government mulls face mask ban at protests: reports
- Hong Kong to ban face masks at protests
- Trump to face impeachment inquiry over Ukraine calls
- Hong Kong enacts emergency law to ban face masks at protests
- Hong Kong to ban face masks in protest crackdown: reports
- Homemade Face Masks
- Hong Kong: Government bans face masks in protest crackdown
Coronavirus latest: Trump wears face mask for the first time have 306 words, post on www.dw.com at December 7, 2020. This is cached page on Europe Breaking News. If you want remove this page, please contact us.
